ArticleBMC microbiology2024
Evaluation of clinical characteristics and risk factors associated with Chlamydia psittaci infection based on metagenomic next-generation sequencing.
Article in BMC microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 16 citations in OpenAlex.
- Rapid diagnosis ofExperimental and therapeutic medicine · 2026Article
- Current status and challenges in the diagnosis and treatment of psittacosis.Infectious diseases & immunity · 2026Review
- Computed tomography findings and severity scores in Chlamydia psittaci pneumonia: a retrospective study of 69 cases with clinical correlation.BMC infectious diseases · 2026Article
- A novel risk stratification model based on creatine kinase and direct bilirubin for identifying severe Chlamydia psittaci pneumonia: a double-center, hypothesis-generating retrospective cohort study.BMC infectious diseases · 2026Article
- Observational
- Hearing loss as the initial manifestation ofIDCases · 2026Article
- Antimicrobial Management of SevereInfection and drug resistance · 2026Review
- Clinical Characteristics of 40 Cases ofInfection and drug resistance · 2026Article
- The relationship betweenFrontiers in medicine · 2026Article
- Early diagnosis and therapy of Chlamydia psittaci pneumonia: insights from chest CT, tNGS, and omadacycline in 34 cases.Frontiers in medicine · 2026Article
- Clinical Features and Risk Factors for Severe Disease in 57 Cases ofInfection and drug resistance · 2026Article
- Clinical management and pharmaceutical care of severeFrontiers in cellular and infection microbiology · 2026Review
- Clinical characteristics and risk factors associated with severe community-acquired pneumonia infected byMicrobiology spectrum · 2025Article
- Estimating the Incubation Period Distribution of Psittacosis: A Retrospective Observational Study.Health science reports · 2025Article
- Chlamydia psittaci pneumonia manifested as pulmonary nodules and cavitary lesions: a case report.BMC infectious diseases · 2025Article
- Clinical characteristics of Chlamydia psittaci pneumonia: a single-center, retrospective study over 5 years.BMC infectious diseases · 2025Article
- Addressing the resurgence of psittacosis: a call for enhanced surveillance and public health measures.Annals of medicine and surgery (2012) · 2025Article
- Analysis of Risk Factors for Severe Pneumonia Progression in Chlamydia psittaci Infections: A Retrospective Study.International journal of general medicine · 2025Article
- Analysis of Clinical Characteristics and Severe Factors of 47 Cases of Psittacosis.Infection and drug resistance · 2025Article
- Clinical Characteristics and Predicting Disease Severity in Chlamydia psittaci Infection Based on Metagenomic Next-Generation Sequencing.Infection and drug resistance · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
introductionPsittacosis is a zoonosis caused by Chlamydia psittaci, the clinical manifestations of Psittacosis range from mild illness to fulminant severe pneumonia with multiple organ failure. This study aimed to evaluate the clinical characteristics of Chlamydia psittaci infection diagnosed based on metagenomic next-generation sequencing(mNGS), as well as the risk factors affecting the progress of Chlamydia psittaci infection, in order to improve the effect of therapeutics.
methodsWe retrospectively analyzed the clinical data of patients infected with chlamydia psittaci in the First Affiliated Hospital of Nanchang University from January 2021 to December 2021. The patient's past medical history, clinical manifestations, laboratory examinations, chest CT results, treatment status, and prognosis data were collected. we also investigated both the pathogenic profile characteristics and the lower respiratory tract microbiota of patients with Chlamydia psittaci pneumonia using mNGS.
resultsAll cases of Chlamydia psittaci in our research have been confirmed by mNGS. Among 46 cases of Chlamydia psittaci pneumonia, Poultry exposure was reported in 35 cases. In severe cases of Chlamydia psittaci pneumonia, Neutrophils, Procalcitonin (PCT), Lactate Dehydrogenase (LDH), Hydroxybutyrate Dehydrogenase (HBDH), Creatine Kinase Isoenzymes-B (CK-MB) and D-Dimer levels were remarkably higher than that of non-severe cases, except for lymphocytes (all P < 0.05). Chest CT scans showed Bilateral (77.8%), multiple lobar lungs (85.2%), pleural effusions (44.4%) involvement in those suffering from severe Chlamydia psittaci pneumonia, whereas its incidence was 0%, 21.1% and 10.5% in non-severe patients, respectively (P < 0.05). Multivariate analysis revealed that higher lymphocyte concentrations (OR 0.836, 95% CI 0.714-0.962, P = 0.041) were the only protective factor for survival. mNGS results indicated that 41.3% of patients (19/46) had suspected coinfections with a coinfection rate of 84.2% (16/19) in the severe group, much higher than that in the non severe group (p < 0.05). No significantly different profiles of lower respiratory tract microbiota diversity were found between non severe group and severe group.
conclusionA history of poultry exposure in patients can serve as an important basis for diagnosing Chlamydia psittaci pneumonia, and patients with severe Chlamydia psittaci pneumonia are more likely to develop elevated inflammatory biomarkers as well as elevated cardiac markers. Higher lymphocyte concentrations are protective factors associated with severe C. psittaci pneumonia. The higher proportion of patients with coinfections in our study supports the use of mNGS for comprehensive early detection of respiratory infections in patients with C. psittaci pneumonia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.